Stock listing

HKEX:9637 Alebund Pharmaceuticals (Jiangsu) Limited (禮邦醫藥) 股價

Follow Alebund Pharmaceuticals (Jiangsu) Limited into a list and get an email when it puts out news.

Share price · HKEX:9637

$20.30 HKD +0.35 (+1.8%)

Close on Nov 20, 2026

Past 3 months -55.9% · daily closes, Jun 29, 2026 – Nov 20, 2026, adjusted for splits
Day range
$19.33 – $20.50 HKDNov 20, 2026
Volume
170,700 sharesNov 20, 2026
Market cap
$4.77B HKDAt the close on Nov 20, 2026 · price × 235.1M shares outstanding
Traded on an average day
$18.04M HKDMedian day 565,650 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · HKEX:9637 · HKD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$20.30+0.35+1.8%$19.33$20.50$19.33170,700
$19.950.000.0%$19.60$20.08$19.27429,600
$19.95-0.15-0.7%$20.86$20.86$19.52321,500
$20.10-0.50-2.4%$20.60$20.88$19.81447,800
$20.60-0.62-2.9%$20.92$21.16$19.39621,800
$21.22+0.22+1.0%$20.46$21.60$20.46235,800
$21.00+1.00+5.0%$19.98$21.02$19.88416,000
$20.00+0.39+2.0%$20.30$20.30$19.29468,649
$19.61+0.43+2.2%$19.19$20.00$19.19567,900
$19.18+0.71+3.8%$18.00$19.55$17.98659,317
$18.47+1.07+6.1%$17.80$18.88$17.281,031,965
$17.40+0.89+5.4%$16.98$17.40$15.651,012,435
$16.51-0.79-4.6%$17.30$18.03$16.001,772,800
$17.30+1.16+7.2%$16.14$17.49$15.20699,662
$16.14-0.60-3.6%$16.74$16.79$15.84210,562
$16.74+0.02+0.1%$17.18$17.22$16.42363,000
$16.72+0.38+2.3%$16.34$16.94$15.85669,097
$16.34+0.39+2.4%$15.95$17.78$15.721,588,521
$15.95+0.36+2.3%$15.00$15.95$14.80381,700
$15.59+0.09+0.6%$15.56$16.20$14.36742,089
$15.50-1.48-8.7%$17.13$17.35$15.211,106,741
$16.98+0.11+0.7%$18.00$19.33$16.902,574,300
$16.87-0.61-3.5%$17.48$25.74$16.817,402,116
$17.48-1.14-6.1%$19.00$19.63$16.891,866,729
$18.62-3.36-15.3%$21.98$21.98$18.62471,600
$21.98-0.24-1.1%$22.22$23.14$21.52509,600
$22.22-2.58-10.4%$24.80$24.80$22.00572,100
$24.80-1.50-5.7%$26.80$26.80$24.70571,919
$26.30-0.70-2.6%$27.10$27.10$26.00517,400
$27.00-1.58-5.5%$28.26$28.80$25.50685,700
$28.58+1.92+7.2%$26.68$29.00$25.68533,470
$26.66+0.36+1.4%$26.30$27.10$25.76234,168
$26.30+0.90+3.5%$25.40$26.90$25.30227,352
$25.40+0.42+1.7%$24.88$25.54$24.60206,700
$24.98+0.28+1.1%$24.96$25.78$24.56459,734
$24.70+1.26+5.4%$24.12$25.28$23.54631,600
$23.44-1.34-5.4%$24.82$24.82$23.12517,300
$24.78-1.12-4.3%$26.00$26.30$24.22224,900
$25.90+0.20+0.8%$25.68$25.90$24.80447,600
$25.70-0.56-2.1%$26.40$26.84$25.70278,900
$26.26-0.50-1.9%$26.30$28.40$26.14728,500
$26.76+1.34+5.3%$26.36$27.70$25.701,042,900
$25.42-0.64-2.5%$26.60$27.50$24.70846,592
$26.06+1.94+8.0%$24.12$26.40$23.141,053,500
$24.12+0.54+2.3%$23.50$24.92$22.681,184,800
$23.58+0.58+2.5%$23.68$27.50$22.782,730,220
$23.00-1.02-4.2%$24.06$24.78$22.48350,700
$24.02-0.98-3.9%$25.00$25.30$23.82563,400
$25.00-0.74-2.9%$26.96$26.96$24.50772,700
$25.74-2.24-8.0%$28.98$28.98$24.061,582,700
$27.98+1.08+4.0%$26.90$28.94$26.901,060,792
$26.90-1.90-6.6%$29.12$29.12$25.802,845,723
$28.80+0.30+1.1%$28.42$29.32$28.10616,300
$28.50-0.40-1.4%$28.76$29.90$27.26329,240
$28.90-1.56-5.1%$30.20$30.68$27.54718,600
$30.46-1.02-3.2%$31.24$32.78$30.46302,600
$31.48+0.22+0.7%$30.64$32.00$30.44233,502
$31.26+0.12+0.4%$31.00$31.72$30.02241,496
$31.14-1.86-5.6%$32.86$33.62$31.00569,100
$33.00-0.90-2.7%$34.24$34.36$33.00585,500
$33.90+1.44+4.4%$31.14$34.78$31.14488,600
$32.46-0.66-2.0%$32.78$34.80$31.62282,700
$33.12-0.22-0.7%$33.30$34.00$32.26301,300
$33.34+0.16+0.5%$33.00$35.46$33.00287,285
Ticker
HKEX:9637
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
HKEX
Currency
HKD

What changed lately

Latest news

All Alebund Pharmaceuticals (Jiangsu) Limited news

Alebund Pharmaceuticals (Jiangsu) Limited on 6ix

Sector
Health care
Industry
Biotechnology
News releases
20 in the last 12 months · 20 in all · newest Nov 20, 2026 · oldest 2026

Valuation

EV/sales 106× against a median of 1.9×: the highest of 6 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$3.79B HKD
P/E
Loss
EV/sales
106×
EV/EBITDA
Negative EBITDA
Price/book
2.9×
Gross margin
44.0%
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.4×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Alebund Pharmaceuticals (Jiangsu) Limited Class H · HKEX:9637US$608.9MUS$483.6Mn/a106×n/a2.9×n/a0.4×n/a
Sagimet Biosciences Inc. - Series A · NASDAQ:SGMTUS$638.7MUS$404.3Mn/an/an/a2.6×n/a0.0×1.96
Gubra A/S · OMXCOP:GUBRAUS$638.5MUS$533.6M2.6×1.4×1.7×4.2×64.1%0.2×n/a
Kura Oncology, Inc. · NASDAQ:KURAUS$634.9MUS$152.6Mn/a1.9×n/a35.4×−369.3%0.6×1.30
Alphamab Oncology · HKEX:9966US$628.9MUS$454.7Mn/a5.5×n/a2.5×−20.1%0.2×n/a
Iambic Therapeutics, Inc. · NASDAQ:IAMUS$621.4MUS$369.4Mn/a39.2×n/an/a−820.0%n/an/a
Janux Therapeutics, Inc. · NASDAQ:JANXUS$616.7M−US$308.6Mn/a−13.3×n/a0.7×−428.7%0.0×0.95
Olema Pharmaceuticals, Inc. · NASDAQ:OLMAUS$615.0MUS$204.6Mn/an/an/a1.7×n/a0.0×1.25
Annexon, Inc. · NASDAQ:ANNXUS$587.7MUS$423.7Mn/an/an/a4.1×n/a0.3×1.63
Design Therapeutics, Inc. · NASDAQ:DSGNUS$577.6MUS$371.5Mn/an/an/a2.9×n/a0.0×1.29
Cullinan Therapeutics, Inc. · NASDAQ:CGEMUS$577.1MUS$289.6Mn/an/an/a2.0×n/a0.0×1.45
Median of the othersUS$619.1MUS$370.5M2.6×1.9×1.7×2.6×−369.3%0.0×1.30

Forecasts

Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
48.73 HKD · Analysts' mean
EPS, year to Dec 2026
-1.46 · 1 analyst
Revenue, year to Dec 2026
153.9M · 3 analysts

Team and board

Officers

OfficerRole
Gavin XIACo-Founder, Chief Executive Officer and Chairman of the Board
Huading ZHANGChief Operating Officer
Jin TIANCo-Founder and Chief Medical Officer
WANG YunChief of Staff

Board

DirectorRole
Gavin XIACo-Founder, Chief Executive Officer and Chairman of the Board
An LUNon-Executive Director
Huading ZHANGChief Operating Officer
Jin TIANCo-Founder and Chief Medical Officer
Justin LEUNGIndependent Non-Executive Director
Shirley XUIndependent Non-Executive Director
WANG YunChief of Staff
Zhui CHENIndependent Non-Executive Director

Financials

Annual, in CNY

Income statement

LineFY2025FY2024
Revenue30.6M6.53M
Cost of revenue17.1M4.14M
Gross profit13.4M2.38M
Research and development372.6M235.4M
Selling, general and administrative52.1M17.2M
Operating income-641.3M-306.9M
Depreciation and amortization44.7M12.5M
EBITDA-596.5M-294.4M
Interest expense110.5M29.4M
Income before tax-751.8M-335.1M
Net income-750.0M-326.0M
Earnings per share, basic-2.21-0.96

Balance sheet

LineFY2025FY2024
Cash and equivalents358.3M343.8M
Short-term investments172.8M22.3M
Receivables0865.0K
Inventory10.3M6.12M
Current assets558.7M388.8M
Total assets1.34B1.11B
Accounts payable67.8M25.9M
Current liabilities239.8M1.94B
Long-term debt545.3M445.3M
Total liabilities836.7M2.45B
Shareholders' equity503.2M-1.33B
Shares outstanding339.9M339.9M

Cash flow

LineFY2025FY2024
Cash from operations-287.9M-249.9M
Capital spending-101.6M-236.7M
Free cash flow-389.5M-486.6M
Change in cash17.0M280.4M

Open Financials

Filings

FilingDateTypeFiled with
Next Day Disclosure ReturnNov 20, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnNov 19, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnNov 18, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnNov 17, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnNov 16, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnNov 13, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnNov 6, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnNov 5, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnNov 4, 2026Next day disclosure returnHKEX
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2026Nov 4, 2026Monthly returnHKEX
All 19 filings
FilingDateTypeFiled with
Next Day Disclosure ReturnNov 3, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnNov 2, 2026Next day disclosure returnHKEX
VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASEOct 20, 2026Other filingsHKEX
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026Oct 6, 2026Monthly returnHKEX
2026 INTERIM REPORTSep 17, 2026Interim reportHKEX
ANNOUNCEMENT OF FINAL OFFER PRICE AND ALLOTMENT RESULTSJun 26, 2026FinancingHKEX
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONSJun 25, 2026List of directorsHKEX
Documents on DisplayJun 17, 2026Other filingsHKEX
PHIP (1st submission)Jun 14, 2026Other filingsHKEX

Open Filings

Cap table

Built by 6ix from Alebund Pharmaceuticals (Jiangsu) Limited Class H’s releases

Common shares
235,131,589
Fully diluted
235,131,589

Fully diluted

LineShares
Common shares235,131,589

Share count over time

CountShares
Nov 22, 2026235,131,589

Open Cap table

Shareholders

HolderSharesValueAs of
Lazard Emerging Markets Opportunities ETF313KUS$1.83MJun 30, 2026
Vanguard International Explorer Fund111KUS$385KJul 31, 2026
The Hartford Healthcare Fund85,600US$297KJul 31, 2026
Vanguard Emerging Markets Select Stock Fund33,600US$117KJul 31, 2026
Nationwide International Small Cap Fund32,500US$113KJul 31, 2026
NYLIM WMC International Research Equity Fund30,000US$104KJul 31, 2026
Hartford Healthcare Hls Fund12,300US$72,017Jun 30, 2026
Victory Science & Technology Fund1,100US$3,821Jul 31, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
An LUNon-Executive Director · Since at least Nov 5, 2026
Gavin XIACo-Founder, Chief Executive Officer and Chairman of the Board · Since at least Aug 7, 2026
Huading ZHANGChief Operating Officer · Since at least Nov 5, 2026
Jin TIANCo-Founder and Chief Medical Officer · Since at least Aug 7, 2026
Justin LEUNGIndependent Non-Executive Director · Since at least Nov 5, 2026
Shirley XUIndependent Non-Executive Director · Since at least Nov 5, 2026
WANG YunChief of Staff · Since at least Nov 5, 2026
Zhui CHENIndependent Non-Executive Director · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Alebund Pharmaceuticals (Jiangsu) Limited.